Revolutionizing Therapies: Psoriasis Breakthroughs and Biosimilar Expansion

Summary

---

Episode Overview

Title: Revolutionizing Therapies: Psoriasis Breakthroughs and Biosimilar Expansion
Host: Pharma and BioTech News
Date: March 19, 2026

This episode offers a concise but comprehensive briefing on recent transformative developments in the pharma and biotech sectors. The focus is on pivotal regulatory approvals, innovative treatment breakthroughs (notably in psoriasis, neurology, and gene therapy), the surging role of biosimilars, the integration of AI, and ongoing strategic realignments in response to industry challenges.

---

Key Discussion Points & Insights

1. Psoriasis Treatment Breakthrough: JJ & Protagonist’s Icotide

• FDA Approval of Icotide: A new once-daily oral therapy for psoriasis.
• Market Disruption: Oral administration poses a significant challenge to injectable competitors, promising increased patient compliance and sales.
• Efficacy Evidence: The Phase III ICONIC trial showed Icotide’s substantial efficacy advantage over Bristol Myers Squibb's Sotyktu.
• Industry Trend: A move toward more patient-friendly medication formats and Protagonist’s entry into immunology markets.
  • Notable Quote:

    “This once daily oral treatment could disrupt a market dominated by injectable therapies.” (B, 00:25)

2. Biosimilar Expansion: Sandoz & Samsung Bioepis Alliance

• Expanded Partnership: Up to five biosimilars to be commercialized, including a version of Takeda's Entyvio.
• Importance: Reflects heightened focus on affordability, global accessibility, and strategic alliances amidst pricing pressures.

3. Precision Oncology: Actinium-225 Plant by TerraPower Isotopes

• Investment: $450 million for a facility producing a rare radiopharmaceutical isotope.
• Strategic Backing: Major support from the Gates Foundation.
• Potential Impact: Securing US and global supplies for targeted cancer treatments with fewer adverse effects.
  • Notable Quote:

    “This move positions TerraPower as a leader in supplying crucial ingredients for targeted cancer therapies...” (B, 01:13)

4. Regulatory Evolution: Animal-Free Drug Testing

• FDA & NIH Initiative: $150 million committed to developing alternatives, such as organ-on-chip technologies.
• Priorities: Ethical innovation and accelerated, safer drug development.

5. Stem Cell Therapy Progress: Aspen Neuroscience

• Parkinson’s Treatment Milestone:
  • All patients in a year-long study showed symptom improvement.
  • Next step: pivotal Phase III trials.
  • Notable Quote:

    “These results underscore the transformative potential of regenerative medicine in tackling neurodegenerative disorders.” (B, 02:05)

6. Business & Strategic Shifts

• Patent Expirations & Competition: Prompting rethinking of portfolios and increased innovation.
• Regional Innovation Hubs:
  • Indiana's $1B initiative targeting 100,000 new life science jobs.
  • Emphasizes economic and community impact of the sector.

7. AI-driven Discovery & Funding Surges

• Xera Therapeutics: Raised $1B for AI-driven drug discovery in inflammation and immunology.
• Crossbow Therapeutics: $77M Series B for T Cell Engager technology in immuno-oncology.
• ROC & Nvidia: Partnership to accelerate drug development via AI integration.
  • Notable Quote:

    “This underscores growing reliance on AI technologies to accelerate drug development timelines.” (B, 03:00)

8. Economic Pressures & Layoffs

• Layoffs at Gossamer Bio & Bicycle Therapeutics: Reflect industry volatility, the need for adaptability.

9. Corporate Governance & Ethics

• Moderna’s CEO Compensation: Under scrutiny during periods of revenue shortfalls.
• GSK & Flovent: Criticisms over pricing, highlighting ethical considerations in access to cardiovascular medications.

10. Cardiology Innovation: Genivalve’s Trilogy Heart Valve

• FDA Approval: New minimally invasive solution for severe aortic regurgitation.
• Impact: Potential for significantly improved patient outcomes.

11. Psychiatric & Niche Disease Advances

• American Psychiatric Association: Dialogues about biomarker-driven mental health diagnoses.
• R1 Therapeutics: $77.5M Series A for kidney disease—signals broad innovation in niche disease spaces.
• Regulatory Setbacks: Aldaira’s third FDA rejection for dry eye drug, underscoring regulatory complexity.

12. Gene & Cell Therapies Progress and Oversight

• Sana Biotechnology: 14 months of insulin production in type 1 diabetes—potentially game-changing.
• Capricor Therapeutics: FDA reconsidering Duchenne muscular dystrophy therapy after new data.
• Unicure: Controversy over Huntington’s therapy efficacy, with direct challenges from FDA officials.
• Ultragenyx: Gene therapy for ammonia reduction in rare diseases demonstrates promise.

13. Strategic Programs and Collaborations

• Pfizer: Discontinuing Ignite program.
• Astellas & CytomX: Ending collaboration.
• Summary Insight: Strategic partnerships and technological innovations remain essential for industry growth and patient care.

---

Notable Quotes & Memorable Moments

• On patient-friendly innovation:

  “This trend towards more patient friendly options is indicative of a broader industry shift...” (B, 00:44)

• On biosimilars' role:

  “Such strategies are becoming increasingly vital.” (B, 00:58)

• On ethical innovation:

  “This initiative emphasizes ethical scientific practices and leverages innovative technologies like organ on chip systems.” (B, 01:37)

• On sector volatility:

  “Layoffs at Gossamer Bio and Bicycle Therapeutics highlight sector volatility and the need for strategic adaptability.” (B, 03:21)

• On data transparency and regulation:

  “An FDA official refutes efficacy claims, emphasizing transparency's role in gaining regulatory approval.” (B, 05:09)

• Industry summary quote:

  “These developments reflect a vibrant yet challenging landscape where scientific breakthroughs continue amid regulatory dynamics that emphasize robust data transparency.” (B, 06:11)

---

Timestamps for Important Segments

• FDA Approval of Icotide for Psoriasis: 00:19 – 00:44
• Biosimilar Market Expansion: 00:44 – 01:10
• TerraPower and Radiopharmaceuticals: 01:10 – 01:28
• Regulatory Changes – Animal Testing Alternatives: 01:29 – 01:47
• Stem Cell Therapy—Aspen Neuroscience: 01:47 – 02:05
• Industry Challenges and Economic Development: 02:06 – 02:27
• Major AI and Immuno-Oncology Funding News: 02:28 – 03:09
• Layoffs and Adaptive Strategies: 03:10 – 03:30
• Corporate Governance and Pricing Ethics: 03:31 – 03:52
• Cardiac and Psychiatric Innovations: 03:53 – 04:26
• Challenges in Gene & Cell Therapy Regulation/Efficacy: 04:27 – 05:39
• Summary and Closing Reflection: 06:01 – end

---

Episode Takeaways

This episode spotlights a rapidly evolving biopharma sector where scientific innovation, patient centricity, and data transparency coalesce with economic realities and regulatory shifts. From next-generation oral therapies and gene editing to the strategic use of AI, the industry’s future appears vibrant—yet complex and competitive. The continual need for collaboration and ethical responsibility underscores every breakthrough.

---

Transcript

[A]

Biotech Daily is now open for sponsors and job of the week listings. If you want to reach biotech or pharma operators, scientists, founders and investors, you can book a single episode, a full week or promote an open role, all directly by visiting sponsor O with AI that's sponsor Owith AI.

[B]

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we explore the latest news and trends shaping this dynamic industry. Significant strides have been made recently, particularly with the FDA's approval of JJ and Protagonist Therapeutics novel psoriasis medication Icotide. This once daily oral treatment could disrupt a market dominated by injectable therapies. The convenience of oral administration is likely to improve patient compliance and drive substantial sales, marking a pivotal moment in psoriasis treatment. The Phase three iconic trial demonstrated substantial efficacy over existing treatments like Bristol Myers Squibs Sotig 2. This trend towards more patient friendly options is indicative of a broader industry shift and signifies protagonists entry into competitive immunology markets. Turning to Biosimilars Sandoz has expanded its partnership with Samsung Bioepus to commercialize up to five biosimilars, including a version of Takeda's ntvo. This collaboration highlights the industry's growing reliance on biosimilars as affordable alternatives to branded biologics. Amidst pricing pressures and a global demand for accessible medications, such strategies are becoming increasingly vital. In an ambitious venture, TerraPower Isotopes, backed by the Gates foundation, is investing $450 million in a plant for producing Actinium 225, a rare isotope used in radiopharmaceuticals. This move positions TerraPower as a leader in supplying crucial ingredients for targeted cancer therapies, an area that promises advancements in precision medicine by offering targeted treatments with fewer side effects. Regulatory landscapes are evolving too, with the FDA and NIH committing $150 million towards alternatives to animal testing in drug development. This initiative emphasizes ethical scientific practices and leverages innovative technologies like organ on chip systems. Such regulatory support is essential for speeding up drug development while ensuring safety standards remain high. Stem cell therapy also sees promising developments with Aspen Neuroscience's treatment for Parkinson's disease. After one year, all treated patients showed symptom improvement, paving the way for pivotal Phase three trials. These results underscore the transformative potential of regenerative medicine in tackling neurodegenerative disorders. As the industry evolves, it faces challenges such as looming patent expirations and intensified competition. These pressures are prompting companies to innovate and reconsider strategies for existing product lines. In response to these challenges, strategic realignments are becoming more common. Meanwhile, Indiana's plan to create 100,000 jobs through a $1 billion strategy highlights regional efforts to establish hubs for life sciences innovation, illustrating the broader economic impact of the biopharma sector. In parallel news, Xera Therapeutics has raised an impressive $1 billion to leverage AI for drug discovery in inflammatory and immunological research. This underscores growing reliance on AI technologies to accelerate drug development timelines. Crossbow Therapeutics reached a significant milestone by securing $77 million in Series B funding to advance its T Cell Engager technology, a promising approach in immuno oncology that harnesses the immune system against cancer cells. Despite these advancements, economic pressures continue to challenge some companies. Layoffs at Gossamer Bio and Bicycle Therapeutics highlight sector volatility and the need for strategic adaptability. Corporate governance remains under scrutiny as Moderna's CEO compensation package reveals executive priorities amidst revenue shortfalls. Meanwhile, GSK faces criticism over its management practices concerning Flovent, which raises ethical concerns about pricing strategies in cardiovascular care. Genivalve's FDA approval for its Trilogy heart valve offers a new option for treating severe aortic regurgitation. Such innovations in minimally invasive procedures could significantly improve patient outcomes. Discussions within the American Psychiatric association regarding biomarkers in mental health diagnosis point towards personalized medicine trends. Integrating biological markers could revolutionize mental health diagnostics and treatment plans. Elsewhere in Oncology Research, R1 Therapeutics, $77.5 million Series A fundraising effort, aims at advancing treatments for kidney disease, a reflection of increased investment interest in niche markets and innovative therapies. Amidst these developments, regulatory hurdles persist. Aldaira faced its third FDA rejection for its dry eye disease drug, a reminder of the unpredictability of regulatory pathways and the importance of aligning closely with FDA expectations. Sana Biotechnology's cell therapy demonstrates sustained insulin production over 14 months in type 1 diabetes, a potential breakthrough offering long term solutions for chronic diseases. The FDA is reconsidering Capricor Therapeutics Duchenne muscular dystrophy cell therapy after reviewing additional clinical data, an example of ongoing dialogues between regulators and biotech firms navigating novel therapy approvals. Unicure's Huntington's disease gene therapy faces controversy as an FDA official refutes efficacy claims, emphasizing transparency's role in gaining regulatory approval. Ultragenics's gene therapy success in reducing ammonia levels highlights gene therapy's growing role in addressing rare diseases, an area seeing increasing investment due to promising clinical outcomes. These stories illustrate that despite challenges, such as Pfizer discontinuing its Ignite program or Astella's ending collaboration with Cytomx due to strategic realignment needs, collaboration remains key. ROC's partnership with Nvidia exemplifies how AI integration can accelerate drug development processes. In conclusion, these developments reflect a vibrant yet challenging landscape where scientific breakthroughs continue amid regulatory dynamics that emphasize robust data transparency. As companies navigate these complexities through strategic partnerships and technological innovations, they remain committed to advancing patient care and sustaining industry growth globally.